Search
Carboplatin Treatment Options in Canada
A collection of 336 research studies where Carboplatin is the interventional treatment. These studies are located in the Canada . Carboplatin is used for conditions such as Non-Small Cell Lung Cancer, Ovarian Cancer and Lung Cancer.
85 - 96 of 336
Show Filters
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Male
Female
Both
Type of Study
Interventional
Observational
Clinical Trial Phase
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
Unknown
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
Active Not Recruiting
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer.
Phase 3, randomized, multicentre study to evaluate the efficacy and safety of dostarlimab versus carboplatin-paclitaxel in patients with MMR deficient relapse or advanced endometrial cancer. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Canberra Hospital, Garran, Not set +94 locations
Canberra Hospital, Garran, Not set
Calvary Mater Newcastle, Waratah, Not set
Princess Margaret Cancer Centre, Toronto, Not set
CHU d'Amiens - Hôpital Sud, Amiens, Not set
Clinique de l'Europe, Amiens, Not set
ICO Paul Papin, Angers, Not set
Centre Hospitalier d'Auxerre, Auxerre, Not set
Institut Sainte Catherine, Avignon, Not set
CH Simone Veil de Beauvais, Beauvais, Not set
CHRU Jean Minjoz, Besançon, Not set
Institut Bergonié, Bordeaux, Not set
CHU Brest, Brest, Not set
Centre François Baclesse, Caen, Not set
Centre Hospitalier William Morey, Chalon-sur-Saône, Not set
ROC 37, Chambray-lès-Tours, Not set
Centre Jean Perrin, Clermont-Ferrand, Not set
GHPSO, Creil, Not set
Centre Hospitalier Intercommunal de Créteil, Créteil, Not set
Centre Georges François Leclerc, Dijon, Not set
CHU de Dijon, Dijon, Not set
Clinique Victor Hugo, Le Mans, Not set
Centre Oscar Lambret, Lille, Not set
Centre Hospitalier Lyon Sud, Lyon, Not set
Centre Léon Bérard, Lyon, Not set
APHM - Hôpital de la Timone, Marseille, Not set
Institut Paoli Calmettes, Marseille, Not set
Hôpital Saint-Joseph, Marseille, Not set
Hôpital de Mont-de-Marsan, Mont de Marsan, Not set
ICM Val d'Aurelle, Montpellier, Not set
Centre Azuréen de Cancérologie, Mougins, Not set
Médipôle de NANCY SAS, Nancy, Not set
Hôpital Privé du Confluent S.A.S., Nantes, Not set
Centre Antoine Lacassagne, Nice, Not set
Institut de cancérologie du gard, Nîmes, Not set
CHU d'ORLEANS, Orléans, Not set
Institut Curie, Paris, Not set
AP-HP Hôpital Pitié-Salpêtrière, Paris, Not set
Hôpital Cochin, Paris, Not set
Groupe Hospitalier Diaconesses-Croix Saint-Simon, Paris, Not set
Hôpital Européen Georges Pompidou, Paris, Not set
Institut Mutualiste Montsouris, Paris, Not set
Centre Hospitalier Général de Pau, Pau, Not set
Centre CARIO - HPCA, Plérin, Not set
CHU de Poitiers - Hôpital de la Milétrie, Poitiers, Not set
CHI de Cornouaille, Quimper, Not set
Institut Jean Godinot, Reims, Not set
Centre Eugène Marquis, Rennes, Not set
Centre Henri Becquerel, Rouen, Not set
Centre Hospitalier Privé de Saint-Grégoire, Saint-Grégoire, Not set
ICO - Centre René Gauducheau, Saint-Herblain, Not set
CHU Saint-Etienne - Pôle de Cancérologie, Saint-Étienne, Not set
Institut de Cancérologie de Strasbourg Europe - ICANS, Strasbourg, Not set
Institut Claudius Régaud, Toulouse, Not set
CHU Bretonneau, Tours, Not set
ICL - Centre Alexis Vautrin, Vandœuvre-lès-Nancy, Not set
Institut Gustave Roussy, Villejuif, Not set
Ospedale degli Infermi, Biella, Not set
Spedali Civili-Università di Brescia, Brescia, Not set
Ospedale Civile degli Infermi, Faenza, Not set
Ospedale "Umberto I", Lugo, Not set
IRCCS Ospedale San Raffaele, Milano, Not set
Istituto Europeo di Oncologia, Milano, Not set
Ospedale "Santa Maria delle Croci", Ravenna, Not set
Azienda Sanitaria Universitaria Friuli Centrale, Udine, Not set
Ehime University Hospital, Ehime, Not set
Kurume University Hospital, Fukuoka, Not set
Fukushima Medical University Hospital, Fukushima, Not set
The Cancer Institute Hospital Of JFCR, Koto-Ku, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Saitama Medical University International Medical Center, Saitama, Not set
National Cancer Center, Gyeonggi-do, Not set
Seoul National University Bundang Hospital, Gyeonggi-do, Not set
Seoul National University Hospital, Seoul, Not set
Yonsei Medical Center Severance Hospital, Seoul, Not set
Asan Medical Center, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Korea University Guro Hospital, Seoul, Not set
Auckland City Hospital, Auckland, Not set
National University Hospital (NUH), Singapore, Not set
National Cancer Centre Singapore (NCCS), Singapore, Not set
Hospital General Universitario de Elche, Elche, Alicante
Hospital Germans Trias i Pujol / ICO Badalona, Badalona, Not set
Hospital Universitario Reina Sofia, Córdoba, Not set
Hospital Universitario de León, León, Not set
Hospital Son Llátzer, Palma De Mallorca, Not set
Hospital Universitario Son Espases, Palma, Not set
Hospital Clínico Universitario Santiago de Compostela, Santiago De Compostela, Not set
Hospital Universitario y Politécnico La Fe, Valencia, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Queen Elizabeth Hospital, Birmingham, Not set
Addenbrooke's Hospital, Cambridge, Not set
Western General Hospital, Edinburgh, Not set
University College London Hospital, London, Not set
Northampton General Hospital NHS Trust, Northampton, Not set
Royal Cornwall Hospital, Truro, Not set
Conditions: Endometrial Cancer
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery
Active Not Recruiting
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.
Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Honor Health, Phoenix, Arizona +147 locations
Honor Health, Phoenix, Arizona
The University of Arizona Cancer Center, Tucson, Arizona
John Muir Health Clinical Research Center, Concord, California
Kaiser Permanente Southern California, Irvine, California
Moores UC San Diego Cancer Center, La Jolla, California
Kaiser Permanente Los Angeles Medical Center, Los Angeles, California
Epic Care, Pleasant Hill, California
Kaiser Permanente Riverside Medical Center, Riverside, California
University of California, Davis Comprehensive Cancer Center, Sacramento, California
Contra Costa Oncology, Walnut Creek, California
John Muir Health Gynecologic Cancer Services, Walnut Creek, California
University of Colorado Health, Aurora, Colorado
University of Connecticut Health Center, Farmington, Connecticut
Smilow Cancer Hospital, New Haven, Connecticut
Yale University School of Medicine, New Haven, Connecticut
AdventHealth Orlando, Orlando, Florida
Women's Cancer Florida/Women's Cancer Associates, Saint Petersburg, Florida
Lewis Cancer & Research Pavilion at St. Joseph's Candler, Savannah, Georgia
The Queens Medical Center, Honolulu, Hawaii
Kapiolani Medical Center for Women and Children/University of Hawaii, Honolulu, Hawaii
Parkview Research Center, Fort Wayne, Indiana
Women's Cancer Care/Mary Bird Perkins Cancer Center, Covington, Louisiana
Tufts Medical Center, Boston, Massachusetts
Lahey Hospital and Medical Center, Burlington, Massachusetts
MetroWest Medical Center, Framingham, Massachusetts
Lowell General Hospital, Lowell, Massachusetts
Tufts Medical Center Cancer Center in Stoneham, Stoneham, Massachusetts
UMass Memorial Medical Center, Worcester, Massachusetts
St. Joseph Mercy Hospital, Ann Arbor, Michigan
Sparrow Hospital, Lansing, Michigan
Minnesota Oncology Hematology - Mercy Hospital, Coon Rapids, Minnesota
Minnesota Oncology Hematology, Edina, Minnesota
University of Minnesota Health - Maple Grove Clinic, Maple Grove, Minnesota
Minnesota Oncology Hematology, Minneapolis, Minnesota
Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota
Park Nicollet Frauenshuh Cancer Center, Saint Louis Park, Minnesota
Minnesota Oncology Hematology, Saint Paul, Minnesota
Nebraska Methodist Hospital, Omaha, Nebraska
Portsmouth Regional Hospital, Portsmouth, New Hampshire
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey
The Valley Hospital (Valley Health), Paramus, New Jersey
Womens Cancer Care Associates, Albany, New York
Montefiore Medical Center PRIME, Bronx, New York
Mount Sinai - PRIME, Lake Success, New York
Mount Sinai The Blavatnik Family Chelsea Medical Center, New York, New York
Icahn School of Medicine at Mount Sinai, New York, New York
Stony Brook University Hospital, Stony Brook, New York
Duke University, Durham, North Carolina
Duke Women's Cancer Care Raleigh, Raleigh, North Carolina
SCC at UH Geauga Medical Center, Chardon, Ohio
University Hospitals of Cleveland, Cleveland, Ohio
Cleveland Clinic Fairview Hospital, Cleveland, Ohio
Cleveland Clinic, Cleveland, Ohio
Ohio State University Wexner Medical Center, Columbus, Ohio
Grandview Medical Center/Kettering Medical Center, Kettering, Ohio
Cleveland Clinic Hillcrest Hospital, Mayfield Heights, Ohio
UH Minoff Health Center - Seidman, Orange Village, Ohio
SCC at St. John's Medical Center, Westlake, Ohio
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Oklahoma Cancer Specialist and Research Institution, LLC, Tulsa, Oklahoma
Willamette Valley Cancer Institute and Research Center, Eugene, Oregon
Northwest Cancer Specialists, P.C.-Portland-Rose Quarter, Portland, Oregon
Magee Women's Hospital of UPMC, Pittsburgh, Pennsylvania
UPMC Hillman Cancer Center at UPMC Passavant, Pittsburgh, Pennsylvania
Women & Infants Hospital of Rhode Island, Providence, Rhode Island
Sanford Research/USD-Sioux Falls, Sioux Falls, South Dakota
Texas Oncology, P.A. - Austin, Austin, Texas
Texas Oncology, P.A., Dallas, Texas
Texas Oncology, P.A. - Fort Worth, Fort Worth, Texas
Memorial Herman Hospital, Houston, Texas
Texas Oncology San Antonio Medical Center, San Antonio, Texas
University of Virginia Health Systems, Charlottesville, Virginia
Virginia Cancer Specialists, Fairfax, Virginia
Virginia Oncology Associates - Hampton, Norfolk, Virginia
VCU Massey Cancer Center, Richmond, Virginia
Carilion Clinic Gynecological Oncology, Roanoke, Virginia
MultiCare Regional Cancer Center - Auburn, Auburn, Washington
MultiCare Regional Cancer Center-Gig Harbor Medical Park, Gig Harbor, Washington
MultiCare Institute for Research and Innovation, Puyallup, Washington
MultiCare Regional Cancer Center - Tacoma, Tacoma, Washington
University of Wisconsin, Madison, Wisconsin
CEMAIC - Centro Medico Privado, Córdoba, Cordoba
Clínica Universitaria Privada Reina Fabiola, Córdoba, Cordoba
Sanatorio de la Mujer, Rosario, Not set
Sanatorio Parque S.A, Salta, Not set
CER San Juan Centro Polivalente de Asistencia e Inv. Clinica, San Juan, Not set
Clinicas Viedma S.A., Viedma, Not set
ZNA Middelheim, Antwerpen, Not set
Cliniques Universitaires Saint-Luc, Bruxelles, Not set
Clinique CHC MontLégia, Liège, Not set
Centro de Pesquisas Clinica Reichow, Blumenau, Not set
Oncosite - Centro de Pesquisa Clinica e Oncologia, Guimaraes, Not set
Centro Gaucho Integrado de Oncologia, Hematologia, Ensino e Pesquisa - Hospital Mae de Deus, Porto Alegre, Not set
Fundação Doutor Amaral Carvalho, San Paolo, Not set
CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia, Santo André, Not set
Clínica São Germano - Oncologia, Sao Paulo, Not set
Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia
City of Health Hospital at Laval (Cité de la Santé de Laval), Laval, Quebec
CHUM Centre de Recherche (affiliated with University of Montreal), Montréal, Quebec
McGill University Health Centre/Glen Site/ Royal Victoria Hospital, Montréal, Quebec
CHUS - Hôpital Fleurimont, Sherbrooke, Quebec
Centro de Investigación Clínica Bradford Hill, Santiago, Not set
Sociedad de Investigaciones Medicas Limitada, Temuco, Not set
Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set
Fakultni nemocnice Kralovske Vinohrady, Prague, Not set
Fakultni nemocnice Bulovka, Praha, Not set
Fakultni nemocnice v Motole, Praha, Not set
Vseobecna fakultni nemocnice v Praze, Praha, Not set
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet, Budapest, Not set
Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Not set
Debreceni Egyetem, Debrecen, Not set
Bacs-Kiskun Megyei Oktatokorhaz, Kecskemét, Not set
Zala Megyei Szent Rafael Korhaz, Zalaegerszeg, Not set
Fortis Hospital Ltd, Bangalore, Not set
Fortis Hospital Ltd, Bengaluru, Not set
All India Institute of Medical Services, Delhi, Not set
Max Super Specialty Hospital, Mohali, Not set
Sushrut Hospital, Mumbai, Not set
Fortis Hospital, Noida, Not set
Deenanath Mangeshkar Hospital, Pune, Not set
Ruby Hall Clinic, Pune, Not set
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo), Monza, Not set
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Not set
Università Campus Bio-Medico di Roma, Rome, Not set
National Cancer Center, Goyang, Not set
Seoul National University Bundang Hospital, Seongnam, Not set
Asan Medical Center, Seoul, Not set
Korea University Guro Hospital, Seoul, Not set
Samsung Medical Center, Seoul, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital, Yonsei University Health System, Seoul, Not set
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set
Severance Hospital Yonsei University Health System, Soeul, Not set
Clinical Medical Research S.C., Orizaba, Veracruz
Investigacion Onco Farmaceutica S. de R.L. de C.V. (OncoTech), La Paz, Not set
Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Not set
SMIQ S. de R.L. de C.V., Querétaro, Not set
Centro Potosino de Investigación Medica S.C., San Luis Potosi, Not set
Hospital Clinic de Barcelona, Barcelona, Catalonia
Hospital Universitari Vall d'Hebron, Barcelona, Catalonia
Hospital de la Santa Creu i Sant Pau, Barcelona, Not set
ICO l'Hospitalet-Hospital Duran i Reynals, L'Hospitalet De Llobregat, Not set
Instituto Valenciano de Oncologia IVO, Valencia, Not set
Taipei Veterans General Hospital, Taipei county, Taipei
Taichung Veterans General Hospital, Taichung, Not set
National Cheng Kung University Hospital, Tainan, Not set
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set
National Taiwan University Hospital, Taipei, Not set
Conditions: Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer, Ovarian Serous Adenocarcinoma, Fallopian Tube Neoplasms, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Peritoneal Cancer, Peritoneal Carcinoma, Peritoneal Neoplasms
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
Recruiting
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations
DESTINY-Lung04 will investigate the efficacy and safety of Trastuzumab Deruxtecan (T-DXd) versus Standard of Care (SoC) as first-line treatment of Non-Small Cell Lung Cancer (NSCLC) with HER2 Exon 19 or 20 mutations Read Less
Gender:
ALL
Ages:
Between 18 years and 123 years
Trial Updated:
07/07/2025
Locations: Research Site, Anchorage, Alaska +162 locations
Research Site, Anchorage, Alaska
Research Site, Los Alamitos, California
Research Site, Los Angeles, California
Research Site, Orange, California
Research Site, San Francisco, California
Research Site, Santa Monica, California
Research Site, Santa Rosa, California
Research Site, Silver Spring, Maryland
Research Site, Boston, Massachusetts
Research Site, Boston, Massachusetts
Research Site, Ann Arbor, Michigan
Research Site, Basking Ridge, New Jersey
Research Site, East Brunswick, New Jersey
Research Site, Middletown, New Jersey
Research Site, Montvale, New Jersey
Research Site, New Brunswick, New Jersey
Research Site, Commack, New York
Research Site, Harrison, New York
Research Site, New York, New York
Research Site, Uniondale, New York
Research Site, Canton, Ohio
Research Site, Columbus, Ohio
Research Site, Pittsburgh, Pennsylvania
Research Site, Dallas, Texas
Research Site, Kennewick, Washington
Research Site, La Crosse, Wisconsin
Research Site, Milwaukee, Wisconsin
Research Site, Graz, Not set
Research Site, Innsbruck, Not set
Research Site, Linz, Not set
Research Site, Rankweil, Not set
Research Site, Wien, Not set
Research Site, Gent, Not set
Research Site, Hasselt, Not set
Research Site, Leuven, Not set
Research Site, Barretos, Not set
Research Site, Blumenau, Not set
Research Site, Brasília, Not set
Research Site, Florianópolis, Not set
Research Site, Natal, Not set
Research Site, Salvador, Not set
Research Site, Sao Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Uberlândia, Not set
Research Site, Vancouver, British Columbia
Research Site, Brampton, Ontario
Research Site, Toronto, Ontario
Research Site, Montreal, Quebec
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Fuzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Jinan, Not set
Research Site, Kunming, Not set
Research Site, Kunming, Not set
Research Site, Linhai, Not set
Research Site, Nanchang, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Shenyang, Not set
Research Site, ShenZhen, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Xiamen, Not set
Research Site, Yangzhou, Not set
Research Site, Zhengzhou City, Not set
Research Site, Vejle, Not set
Research Site, Bordeaux, Not set
Research Site, Dijon, Not set
Research Site, Le Mans Cedex, Not set
Research Site, Lyon, Not set
Research Site, Marseille cedex, Not set
Research Site, Nantes, Not set
Research Site, Rennes Cedex 9, Not set
Research Site, Toulouse Cedex 9, Not set
Research Site, Villejuif Cedex, Not set
Research Site, Berlin-Zehlendorf, Not set
Research Site, Dresden, Not set
Research Site, Erfurt, Not set
Research Site, Heidelberg, Not set
Research Site, Immenhausen, Not set
Research Site, Köln, Not set
Research Site, Mainz, Not set
Research Site, Mannheim, Not set
Research Site, München, Not set
Research Site, Oldenburg, Not set
Research Site, Ravensburg, Not set
Research Site, Würzburg, Not set
Research Site, Hong Kong, Not set
Research Site, Hong Kong, Not set
Research Site, Jordan, Not set
Research Site, Shatin, Not set
Research Site, Bangalore, Not set
Research Site, Delhi, Not set
Research Site, Hyderabad, Not set
Research Site, Mumbai, Not set
Research Site, Nashik, Not set
Research Site, Milan, Not set
Research Site, Monza, Not set
Research Site, Orbassano, Not set
Research Site, Parma, Not set
Research Site, Roma, Not set
Research Site, Verona, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Kashiwa, Not set
Research Site, Matsuyama-shi, Not set
Research Site, Niigata-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yonago-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Goyang-si, Not set
Research Site, Gyeonggi-do, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Cdmx, Not set
Research Site, Culiacán, Not set
Research Site, Guadalajara Jalisco, Not set
Research Site, Merida, Not set
Research Site, Mexico City, Not set
Research Site, Oaxaca, Not set
Research Site, San Luis Potosí, Not set
Research Site, Amsterdam, Not set
Research Site, Groningen, Not set
Research Site, Leiden, Not set
Research Site, Nijmegen, Not set
Research Site, Bystra, Not set
Research Site, Gdańsk, Not set
Research Site, Olsztyn, Not set
Research Site, Przemysl, Not set
Research Site, Warszawa, Not set
Research Site, L'Hospitalet de Llobregat, Not set
Research Site, Madrid, Not set
Research Site, Malaga, Not set
Research Site, Valencia, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Tainan, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Edirne, Not set
Research Site, Izmir, Not set
Research Site, Kadıkoy/Istanbul, Not set
Research Site, Çankaya, Not set
Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
Active Not Recruiting
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed b... Read More
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with etoposide/platinum chemotherapy followed by atezolizumab in the first-line treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). The primary hypothesis is, with respect to overall survival, MK-7684A in combination with the background therapy of etoposide/platinum followed by MK-7684A, is superior to atezolizumab in combination with the background therapy of etoposide/platinum followed by atezolizumab. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/04/2025
Locations: Infirmary Cancer Care ( Site 0022), Mobile, Alabama +139 locations
Infirmary Cancer Care ( Site 0022), Mobile, Alabama
Los Angeles Hematology Oncology Medical Group ( Site 0006), Los Angeles, California
VA West Los Angeles Medical Center ( Site 0004), Los Angeles, California
Boca Raton Regional Hospital-Lynn Cancer Institute ( Site 0014), Boca Raton, Florida
Fort Wayne Medical Oncology and Hematology ( Site 0013), Fort Wayne, Indiana
Dana-Farber Cancer Institute ( Site 0018), Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan ( Site 0001), Grand Rapids, Michigan
Hattiesburg Clinic Hematology/Oncology ( Site 0003), Hattiesburg, Mississippi
Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0005), Lancaster, Pennsylvania
Blue Ridge Cancer Care ( Site 0015), Blacksburg, Virginia
University of Virginia Cancer Center ( Site 0019), Charlottesville, Virginia
Hospital Italiano de Buenos Aires-Clinical Oncology ( Site 0203), Ciudad Autonoma de Buenos Aires, Buenos Aires
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires
Centro de Educación Médica e Investigaciones Clínicas (CEMIC)-Medical Oncology ( Site 0200), Buenos Aires, Caba
Hospital Provincial del Centenario ( Site 0205), Rosario, Santa Fe
Sanatorio Parque ( Site 0202), Rosario, Santa Fe
Nepean Hospital ( Site 2700), Kingswood, New South Wales
Calvary Mater Newcastle ( Site 2703), Waratah, New South Wales
Frankston Hospital-Oncology and Haematology ( Site 2702), Frankston, Victoria
Western Health-Sunshine & Footscray Hospitals-Cancer Services-Cancer Research ( Site 2701), Melbourne, Victoria
Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0505), Linz, Oberosterreich
Kepler Universitätsklinikum ( Site 0507), Linz, Oberosterreich
Medizinische Universität Graz ( Site 0504), Graz, Steiermark
Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 0502), Wien, Not set
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0501), Wien, Not set
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0106), Kingston, Ontario
Lakeridge Health ( Site 0102), Oshawa, Ontario
Anhui Cancer Hospital ( Site 2915), Hefei, Anhui
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2901), Beijing, Beijing
Beijing Peking Union Medical College Hospital ( Site 2921), Beijing, Beijing
Fujian Provincial Cancer Hospital-oncology department ( Site 2904), Fuzhou, Fujian
Harbin Medical University Cancer Hospital-oncology of department ( Site 2920), Harbin, Heilongjiang
Henan Cancer Hospital ( Site 2916), Zhengzhou, Henan
Union Hospital Tongji Medical College Huazhong University of Science and Technology-Medical Oncology ( Site 2912), Wuhan, Hubei
Hubei Cancer Hospital ( Site 2922), Wuhan, Hubei
Hunan Cancer Hospital ( Site 2907), Changsha, Hunan
The First Affiliated Hospital of Soochow University ( Site 2913), Suzhou, Jiangsu
Jilin Cancer Hospital-GCP office ( Site 2909), Changchun, Jilin
The First Hospital of Jilin University ( Site 2914), Changchun, Jilin
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 2910), Xi'an, Shaanxi
Shanghai Chest Hospital-Oncology department ( Site 2900), Shanghai, Shanghai
Fudan University Shanghai Cancer Center ( Site 2908), Shanghai, Shanghai
Sichuan Cancer hospital. ( Site 2923), Chengdu, Sichuan
West China Hospital Sichuan University ( Site 2903), Chengdu, Sichuan
Sir Run Run Shaw Hospital-Medical Oncology ( Site 2906), Hangzhou, Zhejiang
Zhejiang Cancer Hospital-Oncology ( Site 2919), Hangzhou, Zhejiang
Vaasan Keskussairaala-Department of Clinical Oncology ( Site 0700), Vaasa, Pohjanmaa
Oulun yliopistollinen sairaala-Oncology and Hematology ( Site 0702), Oulu, Pohjois-Pohjanmaa
Turku University Hospital-The Department of Pulmonary Medicine ( Site 0701), Turku, Varsinais-Suomi
Assistance Publique Hôpitaux de Marseille - Hôpital Nord ( Site 0805), Marseille, Bouches-du-Rhone
CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 0800), Toulouse, Haute-Garonne
Centre Hospitalier Universitaire de Limoges - Hôpital Dupuyt-Unité d'oncologie thoracique et cutané ( Site 0803), Limoges, Haute-Vienne
Thoraxklinik-Heidelberg gGmbH-Studienzentrum Thoraxonkologie ( Site 0905), Heidelberg, Baden-Wurttemberg
Lungenfachklinik Immenhausen-Thoracic Oncology ( Site 0907), Immenhausen, Hessen
Medizinische Hochschule Hannover-Department of Pneumology ( Site 0901), Hannover, Niedersachsen
LungenClinic Grosshansdorf-Onkologie ( Site 0903), Grosshansdorf, Schleswig-Holstein
SRH Wald-Klinikum Gera-Lungenkrebszentrum ( Site 0900), Gera, Thuringen
Errikos Dunant Hospital Center-Second Department of Oncology and Clinical Trials Unit ( Site 1002), Athens, Attiki
Sotiria Thoracic Diseases Hospital of Athens ( Site 1003), Athens, Attiki
Metropolitan Hospital ( Site 1001), Athens, Attiki
University General Hospital of Heraklion ( Site 1004), Heraklion, Irakleio
European Interbalkan Medical Center ( Site 1000), Thessaloniki, Not set
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 1105), Kecskemét, Bacs-Kiskun
Petz Aladar Egyetemi Oktato Korhaz-Pulmonológia (Dr. Szalai Zsuzsanna) ( Site 1102), Gyor, Gyor-Moson-Sopron
Reformatus Pulmonologiai Centrum-Onkopulmonologiai Jarobeteg Centrum ( Site 1101), Torokbalint, Pest
Somogy Megyei Kaposi Mór Oktató Kórház-Pulmonologiai Osztaly ( Site 1104), Kaposvár, Somogy
St. James's Hospital ( Site 1200), Dublin, Not set
Beaumont Hospital, Dublin-Cancer Clinical Trials & Research Unit ( Site 1201), Dublin, Not set
Rambam Health Care Campus-Oncology ( Site 1301), Haifa, Not set
Shaare Zedek Medical Center-Oncology ( Site 1300), Jerusalem, Not set
Sheba Medical Center-ONCOLOGY ( Site 1302), Ramat Gan, Not set
Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1402), Naples, Campania
Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 1401), Milan, Lombardia
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 1403), Rozzano, Milano
Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1400), Rome, Roma
Aichi Cancer Center ( Site 3016), Nagoya, Aichi
National Cancer Center Hospital East ( Site 3002), Kashiwa, Chiba
National Hospital Organization Shikoku Cancer Center ( Site 3012), Matsuyama, Ehime
Kurume University Hospital ( Site 3014), Kurume, Fukuoka
National Hospital Organization Hokkaido Cancer Center ( Site 3015), Sapporo, Hokkaido
Kanazawa University Hospital ( Site 3006), Kanazawa, Ishikawa
Kanagawa Cancer Center ( Site 3004), Yokohama, Kanagawa
Sendai Kousei Hospital ( Site 3001), Sendai, Miyagi
Niigata Cancer Center Hospital ( Site 3005), Niigata-shi, Niigata
Kansai Medical University Hospital ( Site 3009), Hirakata, Osaka
Shizuoka Cancer Center ( Site 3007), Nagaizumi, Shizuoka
Cancer Institute Hospital of JFCR ( Site 3003), Koto, Tokyo
National Hospital Organization Kyushu Medical Center ( Site 3013), Fukuoka, Not set
Okayama University Hospital ( Site 3011), Okayama, Not set
Chonnam National University Hwasun Hospital-Pulmonology ( Site 2800), Hwasun, Jeonranamdo
Kyungpook National University Chilgok Hospital-Pulmonology ( Site 2801), Deagu, Taegu-Kwangyokshi
Chungnam national university hospital-Department of Internal Medicine ( Site 2802), Daejeon, Taejon-Kwangyokshi
Korea University Guro Hospital-Internal Medicine ( Site 2803), Seoul, Not set
Klaipeda University Hospital-Oncology chemotherapy ( Site 1502), Klaipeda, Klaipedos Miestas
National Cancer Institute-Department of Thoracic Surgery and Oncology ( Site 1501), Vilnius, Vilniaus Miestas
Hospital of Lithuanian University of Health Sciences Kauno klinikos-Pulmonology ( Site 1500), Kaunas, Not set
Arké SMO S.A. de C.V. ( Site 0401), Mexico, Distrito Federal
Hospital Civil Fray Antonio Alcalde-Oncology ( Site 0407), Guadalajara, Jalisco
Actualidad Basada en la Investigación del Cáncer-Lung Cancer ( Site 0403), Guadalajara, Jalisco
iCan Oncology Center Centro Medico AVE ( Site 0406), Monterrey, Nuevo Leon
Centro de Investigacion Clinica de Oaxaca ( Site 0410), Oaxaca, Not set
Medische Centrum Leeuwarden ( Site 1619), Leeuwarden, Fryslan
Ziekenhuis Rijnstate ( Site 1606), Arnhem, Gelderland
Maastricht UMC+-Pulmonary disease ( Site 1602), Maastricht, Limburg
Jeroen Bosch Hospital-Pulmonology ( Site 1605), Den Bosch, Noord-Brabant
Isala, locatie Zwolle-Poli Longziekten ( Site 1612), Zwolle, Overijssel
Erasmus Medisch Centrum ( Site 1621), Rotterdam, Zuid-Holland
Martini Ziekenhuis ( Site 1618), Groningen, Not set
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1709), Siedlce, Mazowieckie
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1700), Warszawa, Mazowieckie
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1703), Przemysl, Podkarpackie
Szpital Specjalistyczny w Prabutach Spolka z o.o. ( Site 1706), Prabuty, Pomorskie
Centrum Pulmonologii i Torakochirurgii w Bystrej ( Site 1707), Bystra, Slaskie
Przychodnia Lekarska KOMED ( Site 1701), Konin, Wielkopolskie
Med-Polonia Sp. z o. o. ( Site 1710), Poznan, Wielkopolskie
Champalimaud Foundation ( Site 1812), Lisbon, Lisboa
Hospital CUF Descobertas ( Site 1815), Lisbon, Lisboa
Centro Hospitalar do Porto - Hospital de Santo António ( Site 1813), Porto, Not set
Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 1810), Porto, Not set
MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 1905), București, Bucuresti
Centrul medical Focus ( Site 1903), București, Bucuresti
Cardiomed SRL Cluj-Napoca ( Site 1900), Cluj-Napoca, Cluj
Centrul de Oncologie Oncolab-Medical Oncology ( Site 1904), Craiova, Dolj
Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1901), Craiova, Dolj
Cabinet Medical Oncomed ( Site 1902), Timisoara, Timis
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 2102), Madrid, Madrid, Comunidad De
H.R.U Málaga - Hospital General-Oncology ( Site 2104), Málaga, Malaga
Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 2100), Barcelona, Not set
Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2103), Sevilla, Not set
Ege University Medicine of Faculty-Chest Diseases Department ( Site 2402), Bornova, Izmir
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 2407), Adana, Not set
Hacettepe Universitesi-oncology hospital ( Site 2409), Ankara, Not set
Memorial Ankara Hastanesi-Medical Oncology ( Site 2406), Ankara, Not set
Ankara Bilkent City Hospital ( Site 2403), Ankara, Not set
Medipol University Medical Faculty-oncology ( Site 2400), Istanbul, Not set
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2401), Istanbul, Not set
I.E.U. Medical Point Hastanesi-Oncology ( Site 2408), Izmir, Not set
The Christie-Clinical Research Facility ( Site 2607), Manchester, England
Mount Vernon Hospital ( Site 2602), Northwood, Hillingdon
Heartlands Hospital-Oncology Research ( Site 2604), Birmingham, Not set
Conditions: Small Cell Lung Carcinoma
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)
Active Not Recruiting
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that... Read More
The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR).
Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with osimertinib, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining osimertinib with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer.
In total the study aims to enroll approximately 586 patients, consisting of approximately 30 patients who will participate in a safety run-in component of the trial, and approximately 556 who will receive osimertinib alone or osimertinib in combination with chemotherapy in the main trial. In the main part of the trial there is a one in two chance of receiving osimertinib alone, and the treatment is decided at random by a computer.
The study involves a Screening Period, Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected patients will attend, on average, approximately 15 visits over the first 12 months and then approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending on the arrangement of medical assessments by the study centre. Read Less
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
07/03/2025
Locations: Research Site, Bellflower, California +152 locations
Research Site, Bellflower, California
Research Site, Fullerton, California
Research Site, La Jolla, California
Research Site, Santa Monica, California
Research Site, Santa Rosa, California
Research Site, West Hollywood, California
Research Site, Whittier, California
Research Site, Orlando, Florida
Research Site, Tampa, Florida
Research Site, Kansas City, Kansas
Research Site, Louisville, Kentucky
Research Site, Boston, Massachusetts
Research Site, Henderson, Nevada
Research Site, Albany, New York
Research Site, Canton, Ohio
Research Site, Philadelphia, Pennsylvania
Research Site, Pittsburgh, Pennsylvania
Research Site, Pittsburgh, Pennsylvania
Research Site, Houston, Texas
Research Site, San Antonio, Texas
Research Site, Blacksburg, Virginia
Research Site, Fairfax, Virginia
Research Site, Vancouver, Washington
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Caba, Not set
Research Site, Caba, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Cordoba, Not set
Research Site, Santa Fe, Not set
Research Site, Camperdown, Not set
Research Site, Chermside, Not set
Research Site, Elizabeth Vale, Not set
Research Site, Heidelberg, Not set
Research Site, Kogarah, Not set
Research Site, Melbourne, Not set
Research Site, Barretos, Not set
Research Site, Florianópolis, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Sao Paulo, Not set
Research Site, São José do Rio Preto, Not set
Research Site, São Paulo, Not set
Research Site, Vitoria, Not set
Research Site, Calgary, Alberta
Research Site, Edmonton, Alberta
Research Site, Toronto, Ontario
Research Site, Santiago, Not set
Research Site, Santiago, Not set
Research Site, Temuco, Not set
Research Site, Viña del Mar, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Haikou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Harbin, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Urumqi, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Zhengzhou, Not set
Research Site, Olomouc, Not set
Research Site, Ostrava - Vitkovice, Not set
Research Site, Praha 5, Not set
Research Site, Praha, Not set
Research Site, Bordeaux Cedex, Not set
Research Site, Lyon, Not set
Research Site, Montpellier, Not set
Research Site, Villejuif Cedex, Not set
Research Site, Belagavi, Not set
Research Site, Bengaluru, Not set
Research Site, Gurgaon, Not set
Research Site, Kolkata, Not set
Research Site, New Delhi, Not set
Research Site, Pune, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Fukuoka, Not set
Research Site, Hidaka-shi, Not set
Research Site, Himeji-shi, Not set
Research Site, Iwakuni-shi, Not set
Research Site, Kanazawa, Not set
Research Site, Kashiwa, Not set
Research Site, Koto-ku, Not set
Research Site, Osaka-shi, Not set
Research Site, Sakai-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sendai-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Yokohama-shi, Not set
Research Site, Cheongju-si, Not set
Research Site, Goyang-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Arequipa, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, San Isidro, Not set
Research Site, Cebu City, Not set
Research Site, Davao City, Not set
Research Site, Iloilo City, Not set
Research Site, Las Pinas, Not set
Research Site, Legazpi City, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Murmansk, Not set
Research Site, Saint Petersburg, Not set
Research Site, Saint Petersburg, Not set
Research Site, Saint-Petersburg, Not set
Research Site, Syktyvkar, Not set
Research Site, Bratislava, Not set
Research Site, Kosice, Not set
Research Site, Poprad, Not set
Research Site, Johannesburg, Not set
Research Site, Port Elizabeth, Not set
Research Site, Rondebosch, Not set
Research Site, Changhua, Not set
Research Site, Hualien City, Not set
Research Site, Kaohsiung, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Taipei, Not set
Research Site, Taipei, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Hat Yai, Not set
Research Site, Khon Kaen, Not set
Research Site, Muang, Not set
Research Site, Cambridge, Not set
Research Site, Leicester, Not set
Research Site, Liverpool, Not set
Research Site, Maidstone, Not set
Research Site, Manchester, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Conditions: Non-Small Cell Lung Cancer
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
Active Not Recruiting
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
The purpose of this study was to evaluate the efficacy and safety of pembrolizumab plus epacadostat, pembrolizumab monotherapy, and the EXTREME regimen (cetuximab + cisplatin or carboplatin + 5-fluorouracil) as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/01/2025
Locations: Pacific Cancer Medical Center, Anaheim, California +72 locations
Pacific Cancer Medical Center, Anaheim, California
UC Davis Comprehensive Cancer Center, Sacramento, California
St. Joseph Heritage Healthcare, Santa Rosa, California
University of Colorado Cancer Center, Aurora, Colorado
Yale Cancer Center, New Haven, Connecticut
Northwest Georgia Oncology Centers PC, Douglasville, Georgia
U of Kansas Cancer Center, Westwood, Kansas
Baptist Health, Louisville, Kentucky
St. Vincent Healthcare Cancer Ctr, Billings, Montana
New Mexico Cancer Care Alliance, Albuquerque, New Mexico
Oklahoma Cancer Specialists and Research, Tulsa, Oklahoma
Providence Portland Med Center, Portland, Oregon
Huntsman Cancer Institute Univ of Utah, Salt Lake City, Utah
Viginia Mason Med Ctr, Seattle, Washington
Chris OBrien Lifehouse, Camperdown, New South Wales
Macquarie University Hospital, North Ryde, New South Wales
Royal Brisbane & Women s Hospital, Herston, Queensland
Landeskrankenhaus Salzburg, Salzburg, Not set
Allgemeines Krankenhaus der Stadt Wien, Wien, Not set
Juravinski Cancer Center Hamilton Health Sciences, Hamilton, Ontario
Princess Margaret Cancer Centre, Toronto, Ontario
Jewish General Hospital, Montreal, Quebec
CHU de Quebec-Universite Laval-Hotel Dieu de Quebec, Quebec, Not set
Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz, Miskolc, Not set
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz Rendelointezet, Szolnok, Not set
Istituto Europeo di Oncologia, Milano, Not set
IRRCS Instituto Clinico Humanitas, Rozzano, Not set
National Cancer Center Hospital East, Kashiwa, Chiba
Kanazawa University Hospital, Kanazawa, Ishikawa
Kanagawa Cancer Center, Yokohama, Kanagawa
Miyagi Cancer Center, Natori, Miyagi
Tohoku University Hospital, Sendai, Miyagi
Hyogo Cancer Center, Akashi, Not set
Kyushu University Hospital, Fukuoka, Not set
Hiroshima University Hospital, Hiroshima, Not set
Hokkaido University Hospital, Hokkaido, Not set
Kobe City Medical Center General Hospital, Kobe, Not set
Kindai University Hospital, Osakasayama City, Not set
Saitama Cancer Center, Saitama, Not set
Shizuoka Cancer Center Hospital and Research Institute, Shizuoka, Not set
The Cancer Institute Hospital of JFCR, Tokyo, Not set
Seoul National University Hospital, Seoul, Not set
Severance Hospital Yonsei University Health System, Seoul, Not set
Asan Medical Center, Seoul, Not set
Mazowiecki Szpital Onkologiczny, Wieliszew, Mazowieckie
Przychodnia Lekarska Komed, Konin, Not set
Zachodniopomorskie Centrum Onkologii, Szczecin, Not set
Inst. Portugues de Oncologia de Coimbra Frencisco Gentil EPE, Coimbra, Not set
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE, Lisboa, Not set
Centro Hospitalar Lisboa Norte EPE - Hospital de Santa Maria, Lisboa, Not set
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE, Porto, Not set
Hospital Germans Trias i Pujol. ICO de Badalona, Badalona, Not set
Hospital General Universitari Vall d Hebron, Barcelona, Not set
Hospital Ramon y Cajal, Madrid, Not set
Hospital Universitario 12 de Octubre, Madrid, Not set
Hospital Infanta Cristina, Madrid, Not set
Hospital de Nuestra Senora de Valme, Sevilla, Not set
Hospital Clinico Lozano Blesa, Zaragoza, Not set
National Cheng Kung University Hospital, Tainan, Not set
National Taiwan University Hospital, Taipei, Not set
Chang Gung Medical Foundation. Linkou, Taoyuan, Not set
Adana Sehir Hastanesi, Adana, Not set
Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Not set
Trakya Universitesi Tip Fakultesi, Edirne, Not set
Istanbul Universitesi Onkoloji Enstitusu, Istanbul, Not set
Medipol Hastanesi, Istanbul, Not set
Ege Universitesi Tip Fakultesi Hastanesi, Izmir, Not set
Inonu Universitesi Turgut Ozal Tip Merkezi, Malatya, Not set
North Middlesex Hospital, London, Not set
University College London Hospitals (UCLH), London, Not set
The Royal Marsden Foundation Trust, London, Not set
The Royal Marsden Nhs Foundation Trust - Chelsea, London, Not set
Musgrove Park Hospital, Taunton, Not set
Conditions: Head and Neck Cancer
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
Active Not Recruiting
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements).
This is a Phase III, randomized, open-label, multicenter, global study to compare the efficacy and safety of Datopotamab Deruxtecan (Dato-DXd) in combination with durvalumab and carboplatin compared with pembrolizumab in combination with histology-specific platinum-based chemotherapy as first-line treatment of adults with stage IIIB, IIIC, or IV NSCLC without actionable genomic alterations (including sensitizing EGFR mutations, and ALK and ROS1 rearrangements). Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
07/01/2025
Locations: Research Site, Phoenix, Arizona +255 locations
Research Site, Phoenix, Arizona
Research Site, Tucson, Arizona
Research Site, Hot Springs National Park, Arkansas
Research Site, Little Rock, Arkansas
Research Site, Springdale, Arkansas
Research Site, Fountain Valley, California
Research Site, Los Angeles, California
Research Site, Orange, California
Research Site, Boulder, Colorado
Research Site, Fort Myers, Florida
Research Site, Jacksonville, Florida
Research Site, Lakeland, Florida
Research Site, Saint Petersburg, Florida
Research Site, West Palm Beach, Florida
Research Site, Hinsdale, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Bettendorf, Iowa
Research Site, Des Moines, Iowa
Research Site, Iowa City, Iowa
Research Site, Baton Rouge, Louisiana
Research Site, Covington, Louisiana
Research Site, Duluth, Minnesota
Research Site, Rochester, Minnesota
Research Site, Hannibal, Missouri
Research Site, Lincoln, Nebraska
Research Site, Lincoln, Nebraska
Research Site, Clifton Park, New York
Research Site, Asheville, North Carolina
Research Site, Canton, Ohio
Research Site, Columbus, Ohio
Research Site, Maumee, Ohio
Research Site, Tulsa, Oklahoma
Research Site, Portland, Oregon
Research Site, Salem, Oregon
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, Philadelphia, Pennsylvania
Research Site, York, Pennsylvania
Research Site, Watertown, South Dakota
Research Site, Memphis, Tennessee
Research Site, Dallas, Texas
Research Site, Fort Worth, Texas
Research Site, Houston, Texas
Research Site, Houston, Texas
Research Site, Irving, Texas
Research Site, Fairfax, Virginia
Research Site, Henrico, Virginia
Research Site, Norfolk, Virginia
Research Site, Renton, Washington
Research Site, Spokane, Washington
Research Site, Tacoma, Washington
Research Site, Appleton, Wisconsin
Research Site, La Crosse, Wisconsin
Research Site, Graz, Not set
Research Site, Rankweil, Not set
Research Site, Wien, Not set
Research Site, Wien, Not set
Research Site, Blumenau, Not set
Research Site, Florianópolis, Not set
Research Site, Fortaleza, Not set
Research Site, Londrina, Not set
Research Site, Porto Alegre, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, Sao Paulo, Not set
Research Site, São Paulo, Not set
Research Site, Taubaté, Not set
Research Site, Vitoria, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Saint John, New Brunswick
Research Site, Brampton, Ontario
Research Site, Kitchener, Ontario
Research Site, Newmarket, Ontario
Research Site, Sudbury, Ontario
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, Montreal, Quebec
Research Site, St-Jerome, Quebec
Research Site, Saskatoon, Saskatchewan
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chengdu, Not set
Research Site, Chengdu, Not set
Research Site, Chongqing, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hefei, Not set
Research Site, Jinan, Not set
Research Site, Kunming, Not set
Research Site, Lanzhou, Not set
Research Site, Liuzhou, Not set
Research Site, Shandong, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shantou, Not set
Research Site, Shenyang, Not set
Research Site, Shenzhen, Not set
Research Site, Taiyuan, Not set
Research Site, Tianjin, Not set
Research Site, Wenzhou, Not set
Research Site, Wuhan, Not set
Research Site, Wuhan, Not set
Research Site, Xiamen, Not set
Research Site, Yangzhou, Not set
Research Site, Zhengzhou, Not set
Research Site, Brest, Not set
Research Site, Creteil, Not set
Research Site, Gleize, Not set
Research Site, Montpellier, Not set
Research Site, Nimes, Not set
Research Site, Paris CEDEX 14, Not set
Research Site, Paris, Not set
Research Site, Rouen, Not set
Research Site, Saint-Quentin, Not set
Research Site, Strasbourg Cedex, Not set
Research Site, Toulon Cedex 9, Not set
Research Site, Toulouse, Not set
Research Site, Tours, Not set
Research Site, Bad Berka, Not set
Research Site, Berlin, Not set
Research Site, Frankfurt A. Main, Not set
Research Site, Gauting, Not set
Research Site, Gütersloh, Not set
Research Site, Hamburg, Not set
Research Site, Kassel, Not set
Research Site, Kiel, Not set
Research Site, Koblenz, Not set
Research Site, Minden, Not set
Research Site, Rosenheim, Not set
Research Site, Velbert, Not set
Research Site, Würzburg, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Athens, Not set
Research Site, Peiraias, Not set
Research Site, Thessaloniki, Not set
Research Site, Thessaloniki, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Gyöngyös - Mátraháza, Not set
Research Site, Kaposvár, Not set
Research Site, Pécs, Not set
Research Site, Szekszárd, Not set
Research Site, Szolnok, Not set
Research Site, Törökbálint, Not set
Research Site, Calicut, Not set
Research Site, Delhi, Not set
Research Site, Delhi, Not set
Research Site, Jaipur, Not set
Research Site, Kolkata, Not set
Research Site, Madurai, Not set
Research Site, Puducherry, Not set
Research Site, Firenze, Not set
Research Site, Lecco, Not set
Research Site, Messina, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Padova, Not set
Research Site, Parma, Not set
Research Site, Peschiera Del Garda, Not set
Research Site, Rozzano, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hamamatsu-shi, Not set
Research Site, Hidaka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Hiroshima-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Okayama-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Sapporo-shi, Not set
Research Site, Sunto-gun, Not set
Research Site, Wakayama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Busan, Not set
Research Site, Cheongju-si, Not set
Research Site, Jinju-si, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon-si, Not set
Research Site, Suwon, Not set
Research Site, Cdmx, Not set
Research Site, Del. Cuauhtemoc, Not set
Research Site, Mexico, Not set
Research Site, San Luis Potosí, Not set
Research Site, Arequipa, Not set
Research Site, Concepción, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Lima, Not set
Research Site, Bydgoszcz, Not set
Research Site, Bystra, Not set
Research Site, Grudziądz, Not set
Research Site, Kielce, Not set
Research Site, Koszalin, Not set
Research Site, Olsztyn, Not set
Research Site, Poznań, Not set
Research Site, Przemysl, Not set
Research Site, Racibórz, Not set
Research Site, Radom, Not set
Research Site, Siedlce, Not set
Research Site, Las Palmas de Gran Canaria, Not set
Research Site, Lugo, Not set
Research Site, Madrid, Not set
Research Site, Santander, Not set
Research Site, Sevilla, Not set
Research Site, Valencia, Not set
Research Site, Zaragoza, Not set
Research Site, Gävle, Not set
Research Site, Linköping, Not set
Research Site, Lund, Not set
Research Site, Stockholm, Not set
Research Site, Uppsala, Not set
Research Site, Hsinchu, Not set
Research Site, Taichung, Not set
Research Site, Tainan City, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan City, Not set
Research Site, Adana, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Aberdeen, Not set
Research Site, Cambridge, Not set
Research Site, Cardiff, Not set
Research Site, Cheltenham, Not set
Research Site, Edinburgh, Not set
Research Site, London, Not set
Research Site, London, Not set
Research Site, Manchester, Not set
Research Site, Middlesborough, Not set
Research Site, Newcastle-Upon-Tyne, Not set
Research Site, Taunton, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh city, Not set
Research Site, Ho Chi Minh, Not set
Conditions: NSCLC
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
Completed
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer.
This study will evaluate the efficacy and safety of niraparib and novel treatment combinations of niraparib as described within each cohort-specific supplement in participants with ovarian, fallopian tube, or primary peritoneal cancer. Cohort A (single arm) includes participants with recurrent ovarian cancer. Cohort B will not be initiated. Cohort C (randomized-2 arms) includes participants with newly diagnosed ovarian cancer. Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: GSK Investigational Site, Birmingham, Alabama +27 locations
GSK Investigational Site, Birmingham, Alabama
GSK Investigational Site, Los Angeles, California
GSK Investigational Site, San Francisco, California
GSK Investigational Site, Stanford, California
GSK Investigational Site, Ventura, California
GSK Investigational Site, Tampa, Florida
GSK Investigational Site, Chicago, Illinois
GSK Investigational Site, Scarborough, Maine
GSK Investigational Site, Baltimore, Maryland
GSK Investigational Site, Boston, Massachusetts
GSK Investigational Site, Boston, Massachusetts
GSK Investigational Site, Rochester, Minnesota
GSK Investigational Site, Saint Louis, Missouri
GSK Investigational Site, New York, New York
GSK Investigational Site, Rochester, New York
GSK Investigational Site, Oklahoma City, Oklahoma
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Houston, Texas
GSK Investigational Site, Seattle, Washington
GSK Investigational Site, Ottawa, Ontario
GSK Investigational Site, Montreal, Quebec
GSK Investigational Site, Montreal, Quebec
GSK Investigational Site, La CoruNa, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Madrid, Not set
GSK Investigational Site, Malaga, Not set
GSK Investigational Site, Pamplona, Not set
Conditions: Ovarian Neoplasms
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Recruiting
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC).
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab in combination with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: Southern Cancer Center Pc, Daphne, Alabama +246 locations
Southern Cancer Center Pc, Daphne, Alabama
Ironwood Cancer and Research Centers, Chandler, Arizona
Arizona Oncology Associates, Pc - Nahoa, Prescott Valley, Arizona
Hoag Memorial Hospital Prebyterian, Newport Beach, California
Compassionate Cancer Care Medical Group, Riverside, California
Sansum Clinic, Santa Barbara, California
Ronald Reagan UCLA Medical Center, Santa Monica, California
UCHealth Memorial Hospital, Colorado Springs, Colorado
Florida Cancer Specialists - South, Fort Myers, Florida
Cancer Specialist of North Florida, Jacksonville, Florida
Cancer Care Centers of Brevard, Inc., Palm Bay, Florida
Woodlands Medical Specialists, Pa, Pensacola, Florida
Florida Cancer Specialists-North, Saint Petersburg, Florida
Emory University - Winship Cancer Institute Wci, Atlanta, Georgia
Illinois Cancer Specialists, Niles, Illinois
American Oncology Partners of Maryland, Bethesda, Maryland
Maryland Oncology Heamtology P.A., Columbia, Maryland
Beth Israel Deaconess Medical Center, Boston, Massachusetts
Dana Farber Cancer Institute; Inv Drg Svc Pharm, Boston, Massachusetts
Dana Farber Cancer Institute At St. Elizabeth'S Medical Center, Brighton, Massachusetts
Dana Farber Brigham Cancer Center, Foxboro, Massachusetts
Dana Farber At Milford Regional Cancer Center, Milford, Massachusetts
Dana Farber/Bwcc in Affiliation With South Shore Hospital, South Weymouth, Massachusetts
Astera Cancer Care, East Brunswick, New Jersey
Regional Cancer Care Associates LLC, Hackensack, New Jersey
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists - Bronx, Bronx, New York
North Shore Hematology Oncology Associates dba NY Cancer and Blood Specialists- New Hyde Park, New Hyde Park, New York
North Shore Hematology Oncology Associates, Patchogue, New York
North Shore Hematology Oncology Associates DBA NY Cancer and Blood Specialists, Port Jefferson Station, New York
Texas Oncology, P.A., McAllen, Texas
Ut Health San Antonio, San Antonio, Texas
Texas Oncology, P.A., Sugar Land, Texas
Texas Oncology-Tyler, Tyler, Texas
Utah Cancer Specialists IHO Corp, Salt Lake City, Utah
Providence Regional Cancer System, Lacey, Washington
VA Puget Sound Health Care System, Seattle, Washington
Instituto Alexander Fleming, Ciudad Autonoma de Buenos Aires, Not set
Fundacion CENIT para la investigacion en Neurociencias, Ciudad Autonoma de Buenos Aire, Not set
Hospital de La Comunidad, Mar del Plata, Not set
Centro de Investigacion Pergamino Sa, Pergamino, Not set
Instituto de Oncologia de Rosario, Rosario, Not set
Sanatorio Parque, Rosario, Not set
Centro Polivalente de Asistencia E Investigacion Clinica Cer San Juan, San Juan, Not set
Centro de Investigaciones Clinicas. Clinica Viedma S.A., Viedma, Not set
CRSA/ St Andrews Hospital, Adelaide, Not set
Flinders Medical Centre (Fmc), Bedford Park, Not set
PSEHOG (Peninsula and South Eastern Haematology and Oncology Group), Frankston, Not set
St George Public Hospital, Kogarah, Not set
Southern Medical Day Care Centre, Wollongong, Not set
Princess Alexandra Hospital, Woolloongabba, Not set
Landeskrankenhaus Feldkirch, Feldkirch, Not set
Klinikum Klagenfurt Pulmologie, Klagenfurt, Not set
Karl Landsteiner Institut Fã¼R Lungenforschung Und Pneumologische Onkologie C/O Klinik Floridsdorf, Vienna, Not set
Az Maria Middelares - Campus Maria Middelares, Gent, Not set
Centre hospitalier Jolimont-Lobbes, Haine Saint-Paul, Not set
Jessa Hospital, Hasselt, Not set
Cliniques Saint Pierre Ottignies (CSPO), Ottignies, Not set
Az Nikolaas, Sint-Niklaas, Not set
Personal Oncologia de Precisao - Cenantron, Belo Horizonte, Not set
Fundaco Universidade de Caxias Do Sul- Instituto de Pesquisas Em Saude Ips-Ucs, Caxias do Sul, Not set
Hospital Erasto Gaertner, Curitiba, Not set
Oncosite - Centro de Pesquisa Clinica Em Oncologia Ltda, Ijui, Not set
Clínica de Neoplasias Litoral Ltda, ItajaĂ-, Not set
Clnica Lacks, Pelotas, Not set
Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Not set
Instituto Nacional de Că'Ncer - Inca, Rio de Janeiro, Not set
Centro de Estudos E Pesquisa de Hematologia E Oncologia - Cepho, Santo Andre, Not set
Instituto de Ensino E Pesquisa Sao Lucas, Sao Paulo, Not set
Instituto Do Cancer Brasil - Unidade Taubate, Taubate, Not set
CHU de Quebec -Universite Laval Hopital de L'Enfant-Jesus, Quebec City, Not set
Centro de Estudios Clinicos Saga Spa, Santiago de Chile, Not set
ONCOVIDA, Santiago, Not set
Orlandi Oncologia, Santiago, Not set
Oncocentro Apys, Vina Del Mar, Not set
Centro de Investigaciones Clinicas Vina Del Mar, ViĂąa Del Mar, Not set
Peking University Cancer Hospital Beijing Cancer Hospital Beijing Institute For Cancer Research, Beijing Sheng, Not set
Peking University Peoples Hospital, Beijing, Not set
Cangzhou Peoples Hospital, Cangzhou, Not set
First Affiliated Hospital of Medical College of Jilin University, Changchun, Not set
Jilin Cancer Hospital, Changchun, Not set
Hunan Cancer Hospital, Changsha, Not set
University of Electronic Science Technology of China UESTC - Sichuan Cancer Hospital Institute SIC, Chengdu, Not set
Chongqing University Cancer Hospital, Chongqing, Not set
Fujian Medical University - Union Hospital Foochow Christian Union Hospital, Fuzhou, Not set
The First Affiliated Hospital Sun Yat-Sen University, Guangzhou, Not set
Affiliated Cancer Hospital and Insititute of Guangzhou Medical University, Guangzhou, Not set
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Not set
Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Not set
The First Affiliated Hospital of College of Medicine Zhejiang University, Hangzhou, Not set
Harbin Medical University Cancer Hospital, Harbin, Not set
Inner Mongolia Medical University- the Affiliated Hospital, Hohhot, Not set
Jiamusi Cancer Hospital, Jiamusi, Not set
Linyi Cancer Hospital, Linyi, Not set
The First Affiliated Hospital of Nanchang University, Nanchang, Not set
Zhongda Hospital, Southeast University, Nanjing, Not set
Shanghai Chest Hospital, Shanghai, Not set
Fudan University Shanghai Cancer Center, Shanghai, Not set
Liaoning Cancer Hospital & Institute, Shenyang, Not set
Union Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Not set
The First Affiliate Hospital of Xi'An Jiaotong University, Xi'an, Not set
Xiangyang Central Hospital, Xianyang, Not set
Henan Cancer Hospital, Zhengzhou, Not set
The First Affiliated Hosptial of Xinjiang Medical University, Ürümqi, Not set
FN Brno Klinika Nemoci Plicnich a TBC, Brno, Not set
Fakultni nemocnice Olomouc FNOL, Olomouc, Not set
Sainte-Catherine Institut du Cancer Avignon-Provence, Avignon, Not set
Hopital Jean Minjoz - CHU de Besancon, Besancon, Not set
Chu de Bordeaux - Hopital Saint Andre, Bordeaux, Not set
Centre Hospitalier Universitaire, CHU, de Poitiers, France, Not set
Hopital Lyon Sud, Lyon, Not set
Centre Leon Berard, Lyon, Not set
Aphm - Hopital Nord, Marseille Cedex 20, Not set
Institut Paoli Calmettes, Marseille, Not set
Chu de Montpellier, Montpellier Cedex 5, Not set
Chu de Nantes, Nantes, Not set
Hopital Prive Du Confluent, Nantes, Not set
Institut Curie, Paris Cedex 05, Not set
Tenon Hospital, Paris, Not set
CHU de Rennes - Hopital Pontchaillou, Rennes, Not set
Hôpital Foch, Suresnes, Not set
Evangelische Lungenklinik Berlin, Berlin, Not set
Klinikum Chemnitz, Chemnitz, Not set
Universitaetsklinikum Essen, Essen, Not set
Klinikum Esslingen Gmbh, Esslingen, Not set
Universitaetsklinikum Freiburg, Freiburg, Not set
University Hospital Giessen, ZIM IV, Giessen, Not set
External pharmacy Fortuna Herstellung GmbH of main site Universitaetsmedizin Mannheim, Mannheim, Not set
University Hospital Mă Nster, Muenster, Not set
Ludwig-Maximilians University Hospital of Munich, Munich, Not set
Sotiria General Hospital of Chest Diseases, Athens, Not set
Metropolitan Hospital - Athens, Athens, Not set
University General Hospital of Heraklion, Heraklion, Not set
University Hospital of Ioannina Uhi, Ioannina, Not set
Metropolitan Hospital, Neo Faliro, Not set
Olympion Hospital, Patras, Not set
Euromedica General Clinic of Thessaloniki, Thessaloniki, Not set
St. Luke's Hospital, Thessaloniki, Not set
Bioclinic Thessaloniki (Galinos Clinic), Thessalonki, Not set
Tuen Mun Hospital, Hong Kong, Not set
Prince of Wales Hospital / The Chinese University of Hong Kong, Hong Kong, Not set
Queen Mary Hospital, Pok Fu Lam, Not set
National Koranyi Institute For Pulmonology, Budapest, Not set
Veszprem Megyei Tudogyogyintezet Farkasgyepu, Farkasgyepu, Not set
Bkmk Hospital, KecskemĂŠt, Not set
Fejer Megyei Szent Gyorgy Korhaz Pulmonologiai Osztaly, Szekesfehervar, Not set
Hetenyi G Korhaz, Onkologiai Kozpont, Szolnok, Not set
Reformatus Pulmonologiai Centrum, Torokbalint, Not set
Istituto Di Candiolo Irccs, Candiolo, Not set
Ospedale San Luca, Lucca, Not set
Azienda Ospedaliero - Universitaria San Luigi Gonzaga, Orbassano, Not set
IFO Regina Elena, Rome, Not set
Ospedale S. Maria Della Misericordia, Udine, Not set
Asst Sette Laghi, Varese, Not set
Azienda Ospedaliera Universitaria Integrata Verona Ospedale Borgo Roma Crc - Centro Ricerche Clinich, Verona, Not set
NHO Shikoku Cancer Center, Ehime, Not set
Kurume University Hospital, Fukoka, Not set
Kyushu Cancer Center, Fukuoka, Not set
Kyushu University Hospital, Fukuoka, Not set
Teine Keijinkai Hospital, Hokkaido, Not set
Hyogo Medical University Hospital, Hyogo, Not set
Kanazawa University Hospital, Ishikawa, Not set
Kanagawa Cancer Center, Kanagawa, Not set
Kitasato University hospital, Kanagawa, Not set
Social Welfare Organization Saiseikai Imperial Gift Foundation, Inc. Saiseikai Kumamoto Hospital, Kumamoto, Not set
University Hospital Kyoto Prefectual University of Medicine, Kyoto, Not set
Matsusaka Municipal Hospital, Mie, Not set
Sendai Kousei Hospital, Miyagi, Not set
Niigata Cancer Center Hospital, Niigata, Not set
Osaka International Cancer Institute, Osaka, Not set
Osaka Toneyama Medical Center, Osaka, Not set
Kansai Medical University Hospital, Osaka, Not set
NHO Kinki-Chuo Chest Medical Center, Osaka, Not set
Dokkyo Medical University Hospital, Tochigi, Not set
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Not set
Juntendo University Hospital, Tokyo, Not set
The Cancer Institute Hospital of JFCR, Tokyo, Not set
Toho University Omori Medical Center, Tokyo, Not set
Iwakuni Clinical Center, Yamaguchi, Not set
Yamaguchi-Ube Medical Center, Yamaguchi, Not set
Yamanashi Prefectural Central Hospital, Yamanashi, Not set
Chungbuk National University Hospital, Cheongjusi, Not set
Kyungpook National University Chilgok Hospital, Daegu, Not set
Samsung Medical Center, Gangnam-Gu, Not set
National Cancer Center, Goyang-si, Not set
Gyeongsang National University Hospital, Jinju-si Gyeongsangnam-do, Not set
Seoul National University Bundang Hospital, Seongnam-si, Not set
Asan Medical Center, Seoul, Not set
Yonsei University Health System - Severance Hospital, Seoul, Not set
The Catholic Univ. of Korea, Seoul St. Marys Hospital, Seoul, Not set
Cryptex Investigacion Clinica Sa de Cv, Cuauhtemoc, Not set
Hospital Civil de Guadalajara Fray Antonio Alcalde, Guadalajara, Not set
Instituto Nacional de Cancerologia, Mexico City, Not set
Centro de Investigacion Clinica de Oaxaca CICLO, Oaxaca, Not set
Amphia Ziekenhuis, Breda, Not set
Leiden University Medical Center, Leiden, Not set
Jeroen Bosch Ziekenhuis Jbz, s-Hertogenbosch, Not set
II Klinika Chorob Pluc i Gruzlicy, Bialystok, Not set
Centrum Terapii Wspolczesnej, Lodz, Not set
Instytut Centrum Zdrowia Matki Polki (Iczmp), Lodz, Not set
SPSK4, Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Not set
Med Polonia Sp. Z O.O., Poznan, Not set
Maria Sklodowska-Curie National Research Institute of Oncology, Warszawa, Not set
Fundacao Champalimaud, Lisbon, Not set
IPO Porto Francisco Gentil, E.P.E., Porto, Not set
Institute of Oncology Prof. Dr. Ion Chiricuta, Cluj- Napoca, Not set
Onco Clinic Consult Sa, Craiova, Not set
Centrul de Oncologie Sfantu Nectarie, Craiova, Not set
SC Oncomed SRL, Jud Timis, Not set
Oncocenter Oncologie Clinica S.R.L, Timisoara, Not set
Vall Hebron University Hospital, Barcelona, Not set
Hospital Clinic I Provincial de Barcelona, Barcelona, Not set
Hospital Universitario Arnau de Vilanova, Lleida, Not set
Hospital General Universitario Gregorio Marañon, Madrid, Not set
Hospital Clinico San Carlos, Madrid, Not set
Hospital Universitario Fundacion Jimenez Diaz, Madrid, Not set
Hospital Regional Universitario Malaga, Malaga, Not set
CHUO, Ourense, Not set
Hosp Univ Virgen Macarena, Sevilla, Not set
Hospital Universitario Virgen de Valme, Sevilla, Not set
Hospital Universitario y Politecnico de La Fe, Valenica, Not set
Hospital Universitario Miguel Servet, Zaragoza, Not set
Kantonsspital Baselland, Liestal, Not set
Kantonsspital St. Gallen, St. Gallen, Not set
Spital Sts Ag, Thun, Not set
Changhua Christian Hospital, Changhua, Not set
China Medical University Hospital, Hsia, Not set
Taichung Veterans General Hospital, Taichung, Not set
National Cheng Kung University Hospital, Tainan, Not set
National Taiwan University Hospital, Taipei, Not set
Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Not set
Taipei Veterans General Hospital, Taipei, Not set
Tri-Service General Hospital, Taipei, Not set
Linkou Chang Gung Memorial Hospital, Taoyuan, Not set
Faculty of Medicine Chulalongkorn University, Bangkok, Not set
Ramathibodi Hospital, Bangkok, Not set
Siriraj Hospital, Bangkok, Not set
Chiang Mai University CMU - Maharaj Nakhon Chiang Mai Hospital Nakorn Chiang Mai Hospital, Chiang Mai, Not set
Prince of Songkla University PSU - Faculty of Medicine, Hat Yai, Not set
Khon Kaen University - Faculty of Medicine-Srinagarind Hospital, Mueang Nonthaburi, Not set
Baskent University, Adana, Not set
Ankara Bilkent City Hospital, Ankara, Not set
Akdeniz University Hospital, Antalya, Not set
Medipol Mega University Hospital, Bağcılar, Not set
Memorial Ankara Hospital, Cankaya/Ankara, Not set
Istanbul Medeniyet University Medical Faculty, Istanbul, Not set
Adana Acibadem Hospital, Seyhan, Not set
Barts Health NHS Trust, London, Not set
Conditions: Metastatic Non Small Cell Lung Cancer
A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Terminated
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779)
The goal of the study is to learn whether Niraparib or Platinum-Taxane Doublet chemotherapy is better in treating participants with Homologous Recombination Deficient (HRd) Stage III/IV Ovarian Cancer (OC). This study is a sub-study of the Master protocol -OPAL (NCT03574779) Read Less
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/25/2025
Locations: GSK Investigational Site, San Francisco, California +20 locations
GSK Investigational Site, San Francisco, California
GSK Investigational Site, Miami, Florida
GSK Investigational Site, Tampa, Florida
GSK Investigational Site, Scarborough, Maine
GSK Investigational Site, Boston, Massachusetts
GSK Investigational Site, Saint Louis, Missouri
GSK Investigational Site, New York, New York
GSK Investigational Site, New York, New York
GSK Investigational Site, Rochester, New York
GSK Investigational Site, Sioux Falls, South Dakota
GSK Investigational Site, Seattle, Washington
GSK Investigational Site, Ottawa, Ontario
GSK Investigational Site, Montreal, Quebec
GSK Investigational Site, Montreal, Quebec
GSK Investigational Site, A Coruña, ES
GSK Investigational Site, Madrid, ES
GSK Investigational Site, Madrid, ES
GSK Investigational Site, Madrid, ES
GSK Investigational Site, Madrid, ES
GSK Investigational Site, Málaga, ES
GSK Investigational Site, Pamplona, ES
Conditions: Ovarian Neoplasms
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
Completed
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemothe... Read More
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemotherapy in participants with advanced tumor specific cohorts. Read Less
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Henry Ford Health System ( Site 0002), Detroit, Michigan +15 locations
Henry Ford Health System ( Site 0002), Detroit, Michigan
John Theurer Cancer Center at Hackensack University Medical Center ( Site 0003), Hackensack, New Jersey
Next Oncology ( Site 0001), San Antonio, Texas
Macquarie University ( Site 0033), Macquarie University, New South Wales
Alfred Health ( Site 0031), Melbourne, Victoria
BC Cancer - Vancouver Center ( Site 0010), Vancouver, British Columbia
Princess Margaret Cancer Centre ( Site 0011), Toronto, Ontario
FALP-UIDO ( Site 0100), Santiago, Region M. De Santiago
Bradfordhill-Clinical Area ( Site 0101), Santiago, Region M. De Santiago
Hadassa Ein Karem Medical Center ( Site 0022), Jerusalem, Not set
Chaim Sheba Medical Center ( Site 0020), Ramat Gan, Not set
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 0091), Siena, Toscana
Istituto Europeo di Oncologia IRCCS-Divisione di Sviluppo di Nuovi Farmaci per Terapie Innovative (, Milano, Not set
Seoul National University Hospital ( Site 0061), Seoul, Not set
Asan Medical Center ( Site 0060), Seoul, Not set
Hospital Clinic i Provincial ( Site 0041), Barcelona, Not set
Conditions: Neoplasms
Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Active Not Recruiting
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (inclu... Read More
This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab ± tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or cytologically documented, unresectable, locally advanced or metastatic transitional cell carcinoma of the urothelium (including renal pelvis, ureters, urinary bladder, and urethra). Read Less
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
06/24/2025
Locations: Research Site, Birmingham, Alabama +221 locations
Research Site, Birmingham, Alabama
Research Site, Bakersfield, California
Research Site, Fullerton, California
Research Site, Los Angeles, California
Research Site, Salinas, California
Research Site, Santa Barbara, California
Research Site, Truckee, California
Research Site, New Haven, Connecticut
Research Site, Washington, District of Columbia
Research Site, Orlando, Florida
Research Site, Chicago, Illinois
Research Site, Fort Wayne, Indiana
Research Site, Kansas City, Kansas
Research Site, Louisville, Kentucky
Research Site, New Orleans, Louisiana
Research Site, Grand Rapids, Michigan
Research Site, Bozeman, Montana
Research Site, New Hyde Park, New York
Research Site, New York, New York
Research Site, New York, New York
Research Site, Rochester, New York
Research Site, Germantown, Tennessee
Research Site, Fort Worth, Texas
Research Site, Buenos Aires, Not set
Research Site, Buenos Aires, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Ciudad de Buenos Aires, Not set
Research Site, Rosario, Not set
Research Site, Box Hill, Not set
Research Site, Elizabeth Vale, Not set
Research Site, Kogarah, Not set
Research Site, Macquarie University, Not set
Research Site, Murdoch, Not set
Research Site, Orange, Not set
Research Site, South Brisbane, Not set
Research Site, St Albans, Not set
Research Site, Curitiba, Not set
Research Site, Fortaleza, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Porto Alegre, Not set
Research Site, Ribeirão Preto, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Rio de Janeiro, Not set
Research Site, Salvador, Not set
Research Site, Santa Maria, Not set
Research Site, Sao Paulo, Not set
Research Site, São José do Rio Preto, Not set
Research Site, São Paulo, Not set
Research Site, Pleven, Not set
Research Site, Plovdiv, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Sofia, Not set
Research Site, Varna, Not set
Research Site, Calgary, Alberta
Research Site, Edmonton, Alberta
Research Site, Vancouver, British Columbia
Research Site, Hamilton, Ontario
Research Site, Ottawa, Ontario
Research Site, Toronto, Ontario
Research Site, Montreal, Quebec
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Beijing, Not set
Research Site, Changchun, Not set
Research Site, Changsha, Not set
Research Site, Changsha, Not set
Research Site, Chongqing, Not set
Research Site, Chongqing, Not set
Research Site, Dalian, Not set
Research Site, Guangzhou, Not set
Research Site, Guangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Hangzhou, Not set
Research Site, Jinan, Not set
Research Site, Nanchang, Not set
Research Site, Nanjing, Not set
Research Site, Shanghai, Not set
Research Site, Shanghai, Not set
Research Site, Shenyang, Not set
Research Site, Suzhou, Not set
Research Site, Tianjin, Not set
Research Site, Tianjin, Not set
Research Site, Urumqi, Not set
Research Site, Wuhan, Not set
Research Site, Xi'an, Not set
Research Site, Brno, Not set
Research Site, Hradec Kralove, Not set
Research Site, Olomouc, Not set
Research Site, Ostrava, Not set
Research Site, Praha 2, Not set
Research Site, Praha 8, Not set
Research Site, Praha, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Budapest, Not set
Research Site, Debrecen, Not set
Research Site, Győr, Not set
Research Site, Kecskemét, Not set
Research Site, Szolnok, Not set
Research Site, Gurgaon, Not set
Research Site, Hubli, Not set
Research Site, Kolkata, Not set
Research Site, Mysuru, Not set
Research Site, Nagpur, Not set
Research Site, Nasik, Not set
Research Site, New Delhi, Not set
Research Site, New Delhi, Not set
Research Site, Pune, Not set
Research Site, Haifa, Not set
Research Site, Jerusalem, Not set
Research Site, Kfar Saba, Not set
Research Site, Petach-Tikva, Not set
Research Site, Ramat Gan, Not set
Research Site, Arezzo, Not set
Research Site, Milano, Not set
Research Site, Milano, Not set
Research Site, Napoli, Not set
Research Site, Orbassano, Not set
Research Site, Parma, Not set
Research Site, Pavia, Not set
Research Site, Roma, Not set
Research Site, Terni, Not set
Research Site, Verona, Not set
Research Site, Bunkyo-ku, Not set
Research Site, Chuo-ku, Not set
Research Site, Fukuoka-shi, Not set
Research Site, Hirosaki-shi, Not set
Research Site, Kanazawa-shi, Not set
Research Site, Kita-gun, Not set
Research Site, Koshigaya-shi, Not set
Research Site, Koto-ku, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kumamoto-shi, Not set
Research Site, Kyoto-shi, Not set
Research Site, Miyazaki-city, Not set
Research Site, Nagasaki-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Nagoya-shi, Not set
Research Site, Niigata-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osaka-shi, Not set
Research Site, Osakasayama-shi, Not set
Research Site, Shinjuku-ku, Not set
Research Site, Suita-shi, Not set
Research Site, Toyama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Yokohama-shi, Not set
Research Site, Goyang-si, Not set
Research Site, Incheon, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Seoul, Not set
Research Site, Suwon, Not set
Research Site, Bacolod, Not set
Research Site, Baguio City, Not set
Research Site, Cebu, Not set
Research Site, Davao City, Not set
Research Site, Makati, Not set
Research Site, Manila, Not set
Research Site, Quezon City, Not set
Research Site, Quezon City, Not set
Research Site, Bialystok, Not set
Research Site, Gdańsk, Not set
Research Site, Grudziądz, Not set
Research Site, Koszalin, Not set
Research Site, Kraków, Not set
Research Site, Olsztyn, Not set
Research Site, Poznan, Not set
Research Site, Radom, Not set
Research Site, Warszawa, Not set
Research Site, Ivanovo, Not set
Research Site, Krasnoyarsk, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Moscow, Not set
Research Site, Nizhniy Novgorod, Not set
Research Site, Nizhniy Novgorod, Not set
Research Site, Omsk, Not set
Research Site, Rostov-on-Don, Not set
Research Site, Saint-Petersburg, Not set
Research Site, St. Petersburg, Not set
Research Site, St. Petersburg, Not set
Research Site, Tyumen, Not set
Research Site, Vologda, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Barcelona, Not set
Research Site, Lugo, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Madrid, Not set
Research Site, Malaga, Not set
Research Site, Santander, Not set
Research Site, Sevilla, Not set
Research Site, Taichung, Not set
Research Site, Taichung, Not set
Research Site, Tainan, Not set
Research Site, Taipei City, Not set
Research Site, Taipei, Not set
Research Site, Taoyuan, Not set
Research Site, Bangkok, Not set
Research Site, Bangkok, Not set
Research Site, Khon Kaen, Not set
Research Site, Mueang, Not set
Research Site, Songkla, Not set
Research Site, Adana, Not set
Research Site, Adapazari, Not set
Research Site, Ankara, Not set
Research Site, Edirne, Not set
Research Site, Istanbul, Not set
Research Site, Izmir, Not set
Research Site, Ha Noi, Not set
Research Site, Hanoi, Not set
Research Site, Hanoi, Not set
Research Site, Ho Chi Minh, Not set
Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer
85 - 96 of 336